Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 4Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 683Neoplasms 596Carcinoma, Non-Small-Cell Lung 292Colorectal Neoplasms 290Prostatic Neoplasms 284Lung Neoplasms 223Melanoma 162Multiple Myeloma 151Neoplasm Metastasis 147Pancreatic Neoplasms 145Head and Neck Neoplasms 144Ovarian Neoplasms 135Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 122Colonic Neoplasms 113Brain Neoplasms 113Squamous Cell Carcinoma of Head and Neck 111Uterine Cervical Neoplasms 108Stomach Neoplasms 104Lymphoma 102Recurrence 101Glioblastoma 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 85Lymphoma, Non-Hodgkin 81Urinary Bladder Neoplasms 78Lymphoma, Follicular 78Hematologic Neoplasms 78Glioma 74Parkinson Disease 4, Autosomal Dominant Lewy Body 73Sarcoma 72

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Nerve Tissue × 1 year × Clear all
NCT04446416 2026-04-09

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

NaviFUS Corporation

Phase NA Completed
6 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡